Verily Leadership

Andrew Conrad, PhD, is the Executive Chairman and Founder of Verily. Previously, he was Chief Scientific Officer of Laboratory Corporation of America (LabCorp). Dr. Conrad co-founded the National Genetics Institute, where he served as Chief Scientific Officer. He is a Working Group Member on the Precision Medicine Initiative and a member of the UCSF-Stanford Center of Excellence in Regulatory Science and Innovation (CERSI) Scientific Advisory Board.

Stephen Gillett is the Chief Executive Officer at Verily, where he leads multi-disciplinary health, technology and business teams to advance the company's precision health purpose. Before his appointment as CEO, Stephen was Verily’s President & COO overseeing engineering, business and commercial operations. Prior to joining Verily, Stephen was co-founder and CEO of Chronicle, an Alphabet cybersecurity company that is now part of Google Cloud. He is an active advisor to GV and X. Prior to Alphabet, Stephen served as EVP, COO and board member at Symantec, a Fortune 500 Enterprise Technology Company. He also served as the EVP and President of Best Buy Digital and Business Operations, and was part of the founding Starbucks transformation leadership team as Chief Information Officer and General Manager of Digital Ventures. Stephen sits on the Board of Directors for Discord, Dutch Bros and the University of Oregon, Phil and Penny Knight Campus for Accelerating Scientific Impact. He was recognized by Amazon in 2019 as a best selling author for his book “From Simi Valley To Silicon Valley.” He holds an MBA from San Francisco State University and a BS from the University of Oregon.

Amy Abernethy is the President of Product Development and Chief Medical Officer at Verily, where she leads teams in the development and delivery of products that bridge the gap between clinical research and care. Dr. Abernethy was most recently Principal Deputy Commissioner of Food and Drugs of the US Food and Drug Administration (FDA) and the agency's acting Chief Information Officer. Prior to her role at the FDA, Dr. Abernethy was Chief Medical Officer, Chief Scientific Officer and Senior Vice President of Oncology of Flatiron Health. Before joining Flatiron, Dr. Abernethy was Professor of Medicine at Duke University School of Medicine and directed the Center for Learning Health Care in the Duke Clinical Research Institute and Duke Cancer Care Research Program in the Duke Cancer Institute. Dr. Abernethy is a hematologist/oncologist and palliative medicine physician who has authored more than 500 publications. She holds a BA in Biochemistry from the University of Pennsylvania, an MD from Duke University School of Medicine, and a PhD in Evidence Based Medicine and Informatics from Flinders University in Australia.

Scott Burke is the Chief Technology Officer at Verily, where he leads the company’s software and hardware engineering, AI and data science, and UX teams in the development of innovative products and platforms that power precision health. Prior to Verily, Scott was Co-founder and Chief Technology Officer for Helix, a leading population genomics company. Before Helix, Scott worked for nine years at Yahoo, most recently as Senior Vice President of Advertising and Data Platforms. Scott also previously led engineering teams at two mobile startups, Seven Networks and PacketHop, and was Vice President of Engineering for WebMD. Scott started his career as a computational physicist at Hewlett-Packard. He holds a bachelor’s degree in physics from Harvey Mudd College in Claremont, California.

Lisa Greenbaum is the Chief Commercial Officer at Verily, where she leads sales, marketing, and customer success teams with a focus on maximizing value for customers and driving a deep understanding of their needs across the organization. Prior to Verily, Lisa was Chief Client Officer at Progyny where she led sales, account management, and channel partnerships. She joined Progyny prior to the IPO and was a key contributor to the company’s growth during her tenure. Before Progyny, Lisa spent 15 years at WebMD where she was Group General Manager of Medscape Professional Services and led sales, account management, product marketing and revenue delivery. Lisa has also held senior sales roles in the pharmaceutical and digital health space at HealthStream, Merck, and Procter & Gamble. She holds a bachelor’s degree from Duke University.

Utpal Koppikar is the Chief Financial Officer at Verily, where he's responsible for the finance, real estate and workplace services (REWS) and corporate development functions. Previously, Utpal was Executive Vice President and Chief Financial Officer at Atara Biotherapeutics where he oversaw the finance, information technology and investor relations functions. Prior to Atara, Utpal held several senior financial leadership positions at Gilead Sciences, including Vice President of Corporate and Operations Finance, where he was responsible for R&D, corporate, G&A, process development and manufacturing, and strategic sourcing. Before joining Gilead, Utpal served in multiple senior finance roles at Amgen. He began his career at Honeywell Aerospace (formerly AlliedSignal). Utpal holds a BS in Aerospace Engineering from the University of Maryland, an MS in aeronautical and astronautical engineering from Stanford University, and an MBA in finance and marketing from The Anderson School at UCLA.

Kerrie Peraino is the Chief People Officer at Verily, where she oversees all People Operations activities, including talent and leadership development, talent acquisition, learning, compensation and benefits, diversity and inclusion and employee relations. Prior to Verily, Kerrie was VP, People Operations, at Google, where she led frontline HR and delivered world-class HR services to over 130,000 Google employees. Before Google, Kerrie spent more than 20 years at American Express in the U.S. and the U.K., where, among other HR roles of increasing responsibility, she served as Chief Diversity Officer, Chief Talent Officer, and Senior Vice President of Global Talent Management. She holds a BA in Communications from Rutgers University and an MA in Corporate Communications from Seton Hall University.

Preston Simons is the Chief Information Officer at Verily, where he is responsible for building out our IT strategies, systems and processes. Previously, Preston was President and Managing Partner of Simons & Associates, LLC, where he consulted companies on driving business value through transformation of organizational practices, business processes, and technology alignment and implementation. He also specialized in merger and acquisition planning and coordination, IT transformation, integration, and technology strategy engagement. Preston has served in C-level positions for several decades across companies such as Aurora Healthcare, Abbott Laboratories (a Fortune 100 life sciences and medical device company), and Smithkline Beecham (GSK). He is a member of the Board of Governors for the Opus College of Business at the University of St. Thomas, Minnesota, and is an Advisory Board member for Infinity Systems, Inc. He is a certified Board Leadership Fellow of the National Association of Corporate Directors. Preston earned his MBA from the Booth School of Business at the University of Chicago and a BS degree in Management and Computer Science from the Illinois Institute of Technology.

Denny is a veteran executive, having spent 35 years in healthcare financing and operations. Prior to serving as CEO of Granular, his background included a four-year tenure as CEO of Hixme, a digital health benefits platform for large employers, and a 20-year tenure with Wellpoint (Anthem), serving as CEO for a number of its nationwide insurance companies. In his earlier career, Denny served Deloitte Consulting for six years as a consultant in the insurance, benefits and healthcare industries, and he spent six years as chief engineer and general manager of the CTX division of IC Industries. Denny’s private equity board involvements have included Renal Ventures Management, Applied Merchant Systems, Westlake Davvar and Skyview Development. He has also held startup advisory and/or board positions with Outpatient, Focal Scan Systems, and Hixme. Denny’s public company board involvements have included Dole Food Company, Salem Communications Corp, Health Management, Inc. and Wellpoint/Anthem.